Introduction from Drug peptide supply about: Bivalirudin/128270-60-0
| English name | Bivalirudin |
| Chinese name | 比伐卢定 |
| CAS NO | 128270-60-0 |
| Peptide sequence | DPhe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu |
| Molecular formula | C98H138N24O33 |
| Molecular weight | 2180.29 |
| storage temperature | 2-8℃ |
| purity | ≥98% |
| Package | 1mg;5mg;10mg;50mg;100mg,1g or according to customer’s detail requirement. |
| Product English synonyms | Bivalirudin Acetate; BivalirudinBG 8967, Hirulog, Hirulog I; Bivalirudin (human) |
What is Bivalirudin?
Bivalirudin is a peptide anticoagulant, a direct thrombin inhibitor, which can be used for anticoagulation in invasive heart disease, especially percutaneous coronary intervention.
Anticoagulant function of bivalirudin
Anticoagulant drug bivalirudin is a new synthetic anticoagulant drug, which is a direct, specific and reversible inhibitor of thrombin. It was initially successfully developed by the Swiss company Biogen, and was later transferred to the Medicines Company of the United States. It was approved for listing in the United States in 2000. Its anticoagulant component is a 20-peptide compound derived from hirudin. Whether it is thrombin in the blood circulation or thrombin bound to the thrombus, bivalirudin can specifically bind to its catalytic site and anion binding site, thereby directly inhibiting the activity of thrombin, and its effect is short-lived, reversible. Early clinical studies have shown that bivalirudin anticoagulation is effective and has a lower incidence of bleeding events, and it is safer to use than traditional heparin anticoagulation. It is mainly used to prevent ischemic complications before and after angioplasty intervention for unstable angina pectoris. In vitro, this product inhibits both soluble and thrombus-bound thrombin, which is not affected by the products released by platelets and prolongs the activated partial thromboplastin time of normal human plasma in a dose-dependent manner. Enzyme time and prothrombin time. For patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).
Contents related to the bivalirudin experiment
Clinical experiments have shown that in the peri-PCI application, the efficacy of bivalirudin is better than the current mainstream combination of unfractionated heparin/low molecular weight heparin + platelet glycoprotein receptor antagonist, especially the bleeding risk is significantly reduced, which greatly improves the use of anticoagulants. safety:
(1) In patients with elective PCI, the incidence of bleeding can be significantly reduced, and the risk of total clinical outcomes is reduced by 14%.
(2) Does not cause antibody-mediated thrombocytopenia.
(3) Reversible combination with thrombin, short half-life, ischemia and hemorrhagic complications are not easy to occur.
(4) The main excretion does not pass through the kidney, and it can be safely used in patients with renal impairment.
Uses of bivalirudin
Bivalirudin as an alternative to unfractionated heparin and platelet glycoprotein IIb/IIIa antagonists
How to buy Bivalirudin in the U. S.
Peptide supplier Remetide specializes in the production and sales of peptides in the USA, Professional Drug peptide R&D, Professional drug peptide seller. Feel free to contact us if you have any questions or inquiries about Peptides.
Hot line:+19498788363
Wechat:americhina
Email:amin@remetide.com